Abstract
The short-term lipid-lowering activity of some nutraceuticals is well known, however there is a lack of knowledge about their long-term effect, especially regarding insulin-resistance parameters and biomarkers of vascular health. This study is a 12-month follow-up randomised clinical trial carried out on 269 non-smoker hyperlipidaemic patients in primary prevention for cardiovascular disease; 214 of them (129 men and 85 women) completed the trial with good compliance. None of the subjects were diabetics or had been treated with antihyperlipidaemic drugs. Seventy-nine normoweight subjects (Group 1) were treated with a combined nutraceutical monakolinberberine-policosand (MBP) mixture associated with a standardised therapeutic lifestyle (TLS) (as defined in the third Adult Treatment Panel of the National Cholesterol Education Program), 85 overweight subjects were treated with MBP-TLS (Group 2) and 50 overweight subjects only with intensified TLS (Group 3). Efficacy parameters (Body Mass Index, fasting plasma glucose, fasting plasma insulin, Homeostasis Model Assessment index, metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, total cholesterol, low-density lipoprotein-C, high-density lipoprotein-C, triglyceride) were evaluated every 4 months. Educational reinforcements were also planned every 4 months. This study demonstrated the long-term efficacy and safety of a combined nutraceutical added to a TLS in overweight and normoweight dyslipidaemic subjects. Berberine- and red yeast rice-based nutraceuticals showed efficacy in body weight reduction and insulin-sensitivity promotion in non-diabetic hyperlipidaemic patients. Favourable effects of a combined nutraceutical in combination with a TLS were observed on biomarkers of vascular remodelling in overweight and normoweight dyslipidaemic subjects.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Nijjar PS, Burke FM, Bloesch A, Rader DJ (2010) Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 4:248–258
Cicero AFG, Brancaleoni M, Laghi L, Donati F, Mino M (2005) Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complem Ther Med 13:273–278
Cicero AFG, Benvenuti C, ARMoweb study Group (2010) Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. Med J Nutr Metab 3:239–246
Cicero AFG, Rovati L, Setnikar I (2007) Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung 57:26–30
Trimarco B, Benvenuti C, Rozza F, Cimmino CS, Giudice R, Crispo S (2011) Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutr Metab 4:133–140
Izzo R, de Simone G, Giudice R, Chinali M, Trimarco V, De Luca N, Trimarco B (2010) Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens 28:1482–1487
Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S (2010) Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 20:656–661
Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, Caminiti G, Sposato B, Massaro R, Grieco F, Rosano G (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 28:1105–1113
Cicero AFG, Derosa G, Bove M, Imola F, Borghi C, Gaddi AV (2009) Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Topics Nutrac Res 7:121–126
European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diab Med 16:716–730
Heding LG (1972) Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8:260–266
Klose S, Borner K (1978) Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 15:121–130
Wahlefeld AW (1974) Triglyceride determination after enzymatic hydrolysis. In: Bermeyer HU (ed.) Methods of enzymatic analysis, 2nd English edn. Academic Press, New York, pp 18–31
Havel RJ, Edr HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
Araki A, Sako Y (1987) Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 422:43–52
Cicero AF, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV (2007) Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 14:193–198
Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101:1689–1693
Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Føonebø V (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 1:4
Klimek M, Wang S, Ogunkanmi A (2009) Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. PT 34:313–327
Cicero AFG, Ertek S (2009) Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol 4:553–563
Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD (2010) Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59:285–292
Xia X, Yan J, Shen Y, Tang K, Yin J, Zhang Y, Yang D, Liang H, Ye J, Weng J (2011) Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One 6:e16556
Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57:712–717
Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93:2559–2565
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cicero, A.F.G., De Sando, V., Benedetto, D. et al. Long-term efficacy and tolerability of a multicomponent lipid-lowering nutraceutical in overweight and normoweight patients. Nutrafoods 11, 55–61 (2012). https://doi.org/10.1007/s13749-012-0018-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13749-012-0018-y